<DOC>
	<DOCNO>NCT00149864</DOCNO>
	<brief_summary>Aim study collect long term safety data enteric-coated mycophenolate sodium 720 mg bid combination cyclosporine with/without steroid regard adverse event , serious adverse event , patient graft survival . After successful completion study CERL080A302 , patient previously receive enteric-coated mycophenolate sodium MMF give opportunity remain enteric-coated mycophenolate sodium convert MMF enteric-coated mycophenolate sodium .</brief_summary>
	<brief_title>Follow-up Study Safety Enteric-coated Mycophenolate Sodium Patients Who Successfully Completed Study CERL080A302</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>First cadaveric , live unrelated living relate donor kidney transplant recipient complete study CERL080A302 Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Renal Transplant , adult , immunosuppressant</keyword>
</DOC>